Amatoxin-containing mushroom poisoning is the leading cause of fatal mushroom ingestions worldwide, responsible for >90% of mushroom-related deaths. [1-3] The toxin α-amanitin inhibits RNA polymerase II, causing hepatocyte apoptosis and progressive liver failure. Ingestion of as few as 1–2 medium-sized mushroom caps can deliver a lethal dose, and amatoxins are heat-stable and water-insoluble — cooking does not eliminate toxicity. [1] Approximately 50 lethal exposures are reported annually in the United States. [1]
1. History
- Timing is the single most important historical clue: GI symptom onset ≥6 hours after mushroom ingestion strongly suggests amatoxin poisoning, distinguishing it from benign GI-irritant mushrooms (onset <6 hours) [4-5]
- Ask specifically: What species was consumed? Where was it foraged? Was it wild or store-bought? Can leftover mushrooms or photos be obtained for mycologist identification?
- How was it prepared (raw, cooked, boiled)? — Cooking does not destroy amatoxins [1]
- How many caps/pieces were consumed? By how many people? (co-ingestants may present simultaneously)
- Exact time of ingestion and exact time of first GI symptoms (vomiting, diarrhea, abdominal pain)
- Symptom progression: initial cholera-like diarrhea → apparent improvement ("quiescent phase") → worsening [1]
- Important negatives: intentional ingestion vs. accidental foraging, co-ingestion of alcohol or other substances, prior episodes
2. Alarm Features
- Onset of diarrhea <8 hours after ingestion — early predictor of fatal outcome (78% accuracy) [6]
- Profuse, cholera-like watery diarrhea with severe dehydration
- Signs of evolving hepatic failure: jaundice, RUQ tenderness, altered mental status, asterixis
- Coagulopathy (bleeding, bruising, oozing from IV sites)
- Metabolic acidosis, hypoglycemia, hypofibrinogenemia, rising ammonia [7]
- Oliguria or anuria suggesting acute kidney injury
- Encephalopathy or seizures (late finding, days 4–7) [1]
- Any clinical deterioration after the "quiescent phase" (24–36 hours) should be treated as ominous
3. Medications
Antidotes and treatments (all should be initiated as early as possible):
- IV Silibinin dihemisuccinate (Legalon SIL) — first-line antidote per ACG guidelines [1]
- Dose: 20–50 mg/kg/day for 48–96 hours, OR 5 mg/kg IV over 1 hour then 20 mg/kg/day for 6 days [1]
- Mechanism: blocks hepatic amatoxin re-uptake via membrane transport inhibition, free radical scavenger [1][8]
- Not FDA-approved in the US; available via emergency IND from the FDA (contact Poison Control) [1]
- Survival rate ~90% with silibinin monotherapy vs. 59% with supportive care alone [9]
- IV Penicillin G — second-line if silibinin unavailable [1]
- Dose: 1,000,000 IU/kg on day 1; 1,500,000 IU/kg on days 2–3 as continuous infusion [1]
- Mechanism: blocks hepatic uptake of α-amanitin
- Combined penicillin + silibinin protocol showed only 1.5% treatment failure vs. 41.7% with silibinin alone in one large series [10]
- IV N-Acetylcysteine (NAC) — adjunctive therapy [1][11]
- Dose: 150 mg/kg over 15 min → 50 mg/kg over 4 hours → 100 mg/kg over 16 hours [1]
- Anaphylactoid reaction incidence ~5% [11]
- Activated charcoal — multi-dose to disrupt enterohepatic circulation [1]
Contraindicated/caution
- Avoid hepatotoxic medications (acetaminophen, statins, etc.)
- Gastric lavage contraindicated if recent surgery, GI hemorrhage, or altered mental status [1]
4. Diet
- NPO initially during the acute GI phase; aggressive IV hydration is the priority
- Severe vomiting and diarrhea cause massive fluid and electrolyte losses — oral intake is typically not tolerated early
- Once GI symptoms resolve (quiescent phase), cautious reintroduction of clear liquids; however, this phase is deceptive and does not indicate recovery
- Monitor and correct hypoglycemia aggressively (IV dextrose) — hepatic glycogen depletion occurs with liver failure [7]
- Long-term: no specific dietary restrictions after recovery, though alcohol avoidance is prudent during hepatic recovery
5. Review of Systems
- GI: nausea, vomiting, profuse watery diarrhea, abdominal cramping (onset 6–12 hours) [1]
- Hepatic: jaundice, RUQ pain, dark urine (onset 24–72 hours)
- Neurologic: confusion, somnolence, asterixis, seizures (late, days 4–7) [1]
- Renal: decreased urine output, flank pain
- Hematologic: easy bruising, bleeding gums, GI hemorrhage (coagulopathy)
- Constitutional: fatigue, weakness, dizziness (dehydration)
- Cardiovascular: palpitations, lightheadedness (hypovolemia)
6. Collateral History and Family History
- Critical: Identify all co-ingestants — anyone who shared the meal must be evaluated even if asymptomatic, as toxin levels vary between individual mushrooms [12]
- Obtain leftover mushrooms, photos, or spore prints for mycologist identification [4]
- Contact local mycological society or poison control for species identification
- Family history is not directly relevant to amatoxin poisoning, but pre-existing liver disease in any co-ingestant worsens prognosis
- Social context: immigrant populations unfamiliar with local toxic species are at higher risk (e.g., Amanita phalloides resembles edible species from other regions) [3][13]
7. Risk Factors
- Wild mushroom foraging — the primary risk factor; misidentification of toxic species as edible [3][13]
- Immigrant/refugee populations who mistake local toxic species for edible varieties from their home countries [3]
- Geographic: Northern California accounts for the vast majority of US cases (98.4% of California Poison Control calls); seasonal peak October–March in temperate climates [14]
- Children: higher toxin-to-body-weight ratio, potentially worse outcomes [15]
- Women and older patients may have worse outcomes [16]
- Pre-existing liver disease
- Delayed presentation (>24 hours after ingestion) dramatically worsens prognosis [12]
- Climate change may be expanding the geographic range of toxic species [17]
8. Differential Diagnosis
- Other amatoxin-containing species: Galerina spp. and Lepiota spp. (same toxidrome) [1]
- Gyromitra syndrome (gyromitrin/monomethylhydrazine): delayed GI symptoms + hepatotoxicity, but also causes hemolysis and methemoglobinemia [5][18]
- Orellanine poisoning (Cortinarius spp.): very delayed onset (2–14 days), primarily nephrotoxic rather than hepatotoxic [18]
- GI-irritant mushrooms: onset typically <6 hours, self-limited, no hepatotoxicity [4]
- Viral hepatitis (HAV, HBV, HEV): must be excluded in any ALF presentation [16]
- Acetaminophen toxicity: similar ALF presentation; check APAP level
- Other causes of ALF: autoimmune hepatitis, ischemic hepatitis, Wilson disease, Budd-Chiari syndrome
- Bacterial gastroenteritis: Salmonella, Shigella, C. difficile — but these lack the characteristic delayed onset and hepatotoxicity pattern
- Key distinguishing feature: The >6-hour latency between ingestion and GI symptom onset is the hallmark that separates potentially lethal mushroom poisoning from benign GI-irritant syndromes [4]
9. Past Medical History
- Pre-existing chronic liver disease (cirrhosis, hepatitis B/C, NAFLD) — significantly worsens prognosis
- Prior episodes of mushroom poisoning
- Chronic kidney disease — impairs renal excretion of amatoxins (60–80% are renally filtered) [1]
- Penicillin allergy — affects second-line antidote choice
- Immunosuppression — relevant if liver transplantation is considered
- Surgical history — relevant for gastric lavage contraindications [1]
10. Physical Exam
Vital signs
- Tachycardia, hypotension (dehydration/hypovolemia from GI losses)
- Fever is uncommon; if present, consider secondary infection
Focused exam
- Abdomen: diffuse tenderness, hyperactive bowel sounds early; RUQ tenderness with hepatomegaly later; assess for ascites
- Skin: jaundice (typically appears day 2–3), petechiae, ecchymoses (coagulopathy)
- Neurologic: mental status assessment (hepatic encephalopathy grading), asterixis, pupil reactivity
- Mucous membranes: dry (dehydration assessment)
- Cardiovascular: capillary refill, orthostatic vitals
- Rectal: assess stool for occult or frank blood (GI hemorrhage occurs in ~21% of cases) [11]
11. Lab Studies
Initial and serial monitoring (q6–12h during acute phase)
- Hepatic panel: AST, ALT (peak ~day 3 post-ingestion; peak AST <4,000 IU/mL is a favorable prognostic sign) [1][11]
- Coagulation: PT/INR (peak INR <2 predicts favorable outcome), Factor V level (>30% favorable) [1][16]
- Bilirubin: total and direct
- BMP: glucose (hypoglycemia), creatinine (AKI develops in 3–19% of cases), electrolytes (dehydration) [11]
- CBC: monitor for pancytopenia, thrombocytopenia [7]
- Ammonia: rising levels indicate hepatic failure
- Lactate: metabolic acidosis marker
- Fibrinogen, D-dimer, FDP: D-dimer >2.5 μg/mL and PT >19.2 seconds at admission predict progression to liver failure [19]
- Lipase: rule out pancreatitis
- Blood gas: assess acid-base status
- Phosphate: hypophosphatemia reported [7]
- Urinary amanitin (ELISA): correlates with severity when obtained 6–47 hours post-ingestion; serum amanitin has no diagnostic value [10]
- Viral hepatitis serologies, APAP level, toxicology screen: to exclude other etiologies [16]
12. Imaging
- Abdominal ultrasound with Doppler: assess liver echotexture, hepatic vasculature (rule out Budd-Chiari), ascites, biliary dilation
- CT abdomen/pelvis: if concern for other surgical pathology or complications (bowel edema, hemorrhage)
- Imaging is not diagnostic for amatoxin poisoning — the diagnosis is clinical and laboratory-based
- Head CT: if encephalopathy develops, to rule out intracranial hemorrhage (reported complication) [10]
13. Special Tests
- Urinary amanitin assay (ELISA or LC-MS/MS): most useful confirmatory test when available; best obtained 6–47 hours post-ingestion [10][13]
- Mycologist consultation: species identification from leftover mushrooms, photos, or spore prints is critical [4]
- Poison Control Center: contact immediately (1-800-222-1222 in the US) — can facilitate emergency IND access to IV silibinin [1]
- Prognostic scoring systems:
- Escudie criteria: 100% accuracy for predicting 28-day mortality; can be applied before encephalopathy develops [1][6]
- Ganzert criteria: prothrombin index <25% + creatinine >106 μmol/L from day 3 onward (sensitivity 100%, specificity 98%) [20]
- King's College Criteria: validated for ALF from amatoxin poisoning [21]
- Key favorable prognostic markers: peak AST <4,000, peak INR <2, Factor V >30% [1][16]
14. ECG
- ECG is not a primary diagnostic tool for amatoxin poisoning
- Obtain baseline ECG to assess for:
- Electrolyte-related changes (hypokalemia from GI losses — U waves, QT prolongation)
- Tachycardia from dehydration
- Monitor for arrhythmias in the setting of multiorgan failure and electrolyte derangements
- No pathognomonic ECG findings for amatoxin poisoning
15. Assessment
Amatoxin poisoning follows a classic triphasic clinical course: [1]
- Phase I (6–12 hours post-ingestion): Cholera-like gastroenteritis — profuse watery diarrhea, vomiting, abdominal cramps, severe dehydration
- Phase II (24–36 hours): Deceptive "quiescent phase" — clinical symptoms improve, but transaminases begin rising. This is the critical window where patients may be falsely reassured and discharged
- Phase III (days 4–7): Progressive hepatic failure with coagulopathy, acidosis, encephalopathy, seizures, renal failure, and potential death [1]
Severity stratification: Transplantation-free survivors have significantly lower peak AST, ALT, bilirubin, and INR compared to those requiring transplant or dying. [9] Overall survival with active treatment is ~84%; with supportive care alone, only 59%. [9]
16. Treatment Plan
Initial stabilization (ED)
- Aggressive IV fluid resuscitation — target urine output 100–200 mL/hr for 4–5 days [1]
- Correct electrolytes (K⁺, Mg²⁺, Ca²⁺, PO₄³⁻), glucose
- Activated charcoal — multi-dose (50 g q4h or 25 g q2h) even if presentation is delayed, to interrupt enterohepatic circulation [1]
- Gastric lavage only if within 1 hour of ingestion (rarely feasible given delayed symptom onset) [1]
Antidote therapy (initiate ASAP)
- IV Silibinin 20–50 mg/kg/day for 48–96 hours (first-line) [1]
- IV Penicillin G 1,000,000 IU/kg day 1, then 1,500,000 IU/kg days 2–3 (second-line, or combined with silibinin) [1][10]
- IV NAC per standard protocol (adjunctive) [1][11]
ICU management
- Serial labs q6–12h (LFTs, coags, renal function, glucose, ammonia, lactate)
- Monitor for and treat hepatic encephalopathy, coagulopathy, hypoglycemia
- FFP/cryoprecipitate only for active bleeding (not to correct INR prophylactically, as INR is a prognostic marker)
- Hemodialysis, hemoperfusion, and plasmapheresis are of limited benefit due to rapid amatoxin absorption and renal excretion; plasmapheresis may serve as a bridge to transplant for coagulopathy management [1][17]
Liver transplantation
- Definitive therapy for irreversible ALF [1]
- Initiate transplant evaluation early — do not wait for encephalopathy [1][6]
- Apply Escudie or Ganzert criteria from day 3 onward [6][20]
17. Disposition
- All suspected amatoxin ingestions require hospital admission — there is no safe discharge from the ED
- ICU admission for any patient with:
- Confirmed or strongly suspected amatoxin ingestion
- Elevated transaminases or coagulopathy at presentation
- Hemodynamic instability or severe dehydration
- Encephalopathy
- Early transfer to a liver transplant center if:
- Peak AST ≥4,000 IU/mL [16]
- INR ≥2 or rising [16]
- Factor V <30% [1]
- Prothrombin index <25% with creatinine >106 μmol/L from day 3 [20]
- Onset of diarrhea <8 hours after ingestion [6]
- Consult: Poison Control, toxicology, hepatology/transplant surgery, mycologist
18. Follow Up / Return Precautions
- Survivors without transplant: follow-up LFTs, renal function, and coagulation studies at 1 week, 2 weeks, and 1 month post-discharge
- Late recovery of liver function is possible even after day 4 post-ingestion [15]
- Transplant recipients: standard post-transplant immunosuppression monitoring and follow-up
- Patient counseling:
- Never consume wild mushrooms unless identified by an expert mycologist
- Cooking, boiling, drying, or freezing does NOT destroy amatoxins [1]
- Toxic species closely resemble edible varieties and cannot be reliably distinguished visually [3][13]
- Seek immediate medical attention for any GI symptoms occurring ≥6 hours after wild mushroom ingestion [4]
- Return immediately for: recurrence of vomiting/diarrhea, jaundice, dark urine, confusion, bleeding, decreased urine output
References
1. Acute Liver Failure Guidelines. — Shingina A, Mukhtar N, Wakim-Fleming J, et al. The American Journal of Gastroenterology. 2023.
2. Amanita Phalloides Poisoning: Mechanisms of Toxicity and Treatment. — Garcia J, Costa VM, Carvalho A, et al. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association. 2015.
3. Recent Advances in Toxic Wild Mushroom Distribution and Social Epidemiology. — Yaneva G, Dimitrova T, Cherneva D, et al. International Journal of Environmental Research and Public Health. 2026.
4. Mushroom Poisoning. — Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Deutsches Arzteblatt International. 2020.
5. Clinical Symptomatology and Management of Mushroom Poisoning. — Köppel C. Toxicon : Official Journal of the International Society on Toxinology. 1993.
6. Amanita Phalloides Poisoning: Reassessment of Prognostic Factors and Indications for Emergency Liver Transplantation. — Escudié L, Francoz C, Vinel JP, et al. Journal of Hepatology. 2007.
7. Liver Transplantation for Severe Amanita Phalloides Mushroom Poisoning. — Pinson CW, Daya MR, Benner KG, et al. American Journal of Surgery. 1990.
8. Legalon® SIL: The Antidote of Choice in Patients With Acute Hepatotoxicity From Amatoxin Poisoning. — Mengs U, Pohl RT, Mitchell T. Current Pharmaceutical Biotechnology. 2012.
9. Amanitin Intoxication: Effects of Therapies on Clinical Outcomes - A Review of 40 Years of Reported Cases. — Tan JL, Stam J, van den Berg AP, et al. Clinical Toxicology. 2022.
10. Results of Diagnostics and Treatment of Amanita Phalloides Poisoning in Slovakia (2004-2020). — Dluholucký S, Snitková M, Knapková M, Cibirová M, Mydlová Z. Toxicon : Official Journal of the International Society on Toxinology. 2022.
11. -Acetylcysteine as a Treatment for Amatoxin Poisoning: A Systematic Review. — Liu J, Chen Y, Gao Y, et al. Clinical Toxicology. 2020.
12. Wild Mushroom Poisoning: A Case Study of Amatoxin-Containing Mushrooms and Implications for Public Health. — He Z, Li X, Feng M, et al. Toxicon : Official Journal of the International Society on Toxinology. 2024.
13. Investigation of Amanita Molliuscula Poisoning Outbreaks in Heilongjiang Province, China. — Song L, Zhong J, Zhou J, et al. Clinical Toxicology. 2025.
14. A Ten-Year Retrospective California Poison Control System Experience With Possible Amatoxin Mushroom Calls. — Albertson TE, Clark RF, Smollin CG, et al. Clinical Toxicology. 2023.
15. Successful Outcome of Severe Amanita Phalloides Poisoning in Children. — Grabhorn E, Nielsen D, Hillebrand G, et al. Pediatric Transplantation. 2013.
16. Features of Patients With Severe Hepatitis Due to Mushroom Poisoning and Factors Associated With Outcome. — Bonacini M, Shetler K, Yu I, Osorio RC, Osorio RW. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2017.
17. Increasing Incidence of Mycotoxicosis in South-Eastern Germany: A Comprehensive Analysis of Mushroom Poisonings at a University Medical Center. — Stöckert P, Rusch S, Schlosser-Hupf S, et al. BMC Gastroenterology. 2024.
18. Mushroom Poisoning: A Proposed New Clinical Classification. — White J, Weinstein SA, De Haro L, et al. Toxicon : Official Journal of the International Society on Toxinology. 2019.
19. From Liver Injury to Failure: Identification of Predictive Biomarkers in Suspected Amatoxin-Containing Mushroom Poisoning-a Retrospective Case Analysis. — Ma X, Zhou W, Bu B, et al. Toxicon : Official Journal of the International Society on Toxinology. 2025.
20. Indication of Liver Transplantation Following Amatoxin Intoxication. — Ganzert M, Felgenhauer N, Zilker T. Journal of Hepatology. 2005.
21. Acute Liver Failure Due to Amanita Phalloides Poisoning: Therapeutic Approach and Outcome. — Kieslichova E, Frankova S, Protus M, et al. Transplantation Proceedings. 2018.